The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 43)
Research Grant, 2018
In the past, we demonstrated that entry of CCR2-positive monocytes into the brain is required for alpha-synuclein-induced inflammation and neurodegeneration in a model of Parkinson's disease (PD) with alpha-synuclein features. We genetically engineered the models to lack CCR2, a protein on the monocyte surface that enables them to enter the brain. Using these models, we showed tha...
Researchers: Ashley S. Harms, PhD
Research Grant, 2017
Dystonia and Parkinson's disease (PD) are closely related movement disorders. Dystonia is characterized by painful, prolonged muscle contractions that cause involuntary, repetitive twisting and sustained muscle contractions. Some experts estimate that 40 percent of people with PD experience dystonia as an early symptom or complication of treatment. Deep brain stimulation (DBS) is ...
Researchers: Harrison C. Walker, MD
Access to Data and Biospecimens, 2017
The G2019S mutation in the LRRK2 gene is responsible for thousands Parkinson disease (PD) cases. But, not all of the mutation carriers will develop PD. Currently, clinicians cannot predict or discriminate on a biochemical or genetic level G2019S-LRRK2 carriers that will develop PD from those that will not. Our previous study found a convenient way to detect mutant-associa...
Researchers: Andrew West, PhD
Research Grant, 2016
Promising Outcomes of Original Grant:
We aim to determine if hyperactivation of the JAK/STAT (cellular signaling) pathway is involved in Parkinson's disease pathology. Using a pre-clinical model of PD, we found that pharmacologic inhibition of the JAK/STAT pathway prevented both neuroinflammatory and neurodegenerative responses in the alpha-synuclein model of PD. Our hypothesis was verified by our ...
Research Grant, 2016
Loss-of-function mutations in parkin cause approximately 50% of cases of early-onset Parkinson's disease (PD). Parkin selectively targets impaired mitochondria (powerhouses of the cell) for degradation (break down). Recent structural studies of parkin have revealed that this protein exists in an auto-inhibited (shut "off") state. This detailed structural knowledge has enabled the ...
Researchers: Matthew S. Goldberg, PhD